BE2014C063I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C063I2
BE2014C063I2 BE2014C063C BE2014C063C BE2014C063I2 BE 2014C063 I2 BE2014C063 I2 BE 2014C063I2 BE 2014C063 C BE2014C063 C BE 2014C063C BE 2014C063 C BE2014C063 C BE 2014C063C BE 2014C063 I2 BE2014C063 I2 BE 2014C063I2
Authority
BE
Belgium
Application number
BE2014C063C
Other languages
French (fr)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35242158&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C063(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BE2014C063I2 publication Critical patent/BE2014C063I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
BE2014C063C 2004-04-27 2014-10-02 BE2014C063I2 (h)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27

Publications (1)

Publication Number Publication Date
BE2014C063I2 true BE2014C063I2 (h) 2024-08-08

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C063C BE2014C063I2 (h) 2004-04-27 2014-10-02

Country Status (38)

Country Link
US (9) US7498440B2 (h)
EP (3) EP3111936A1 (h)
JP (2) JP5014121B2 (h)
KR (2) KR101037026B1 (h)
CN (2) CN102040602A (h)
AP (1) AP2213A (h)
AR (1) AR050902A1 (h)
AU (1) AU2005237576B2 (h)
BE (1) BE2014C063I2 (h)
BR (1) BRPI0510170B8 (h)
CA (2) CA2755954C (h)
CY (3) CY1113196T1 (h)
DK (2) DK2570128T3 (h)
EA (2) EA015033B1 (h)
EC (1) ECSP066940A (h)
ES (2) ES2392848T4 (h)
FR (1) FR14C0075I2 (h)
HR (2) HRP20120832T1 (h)
HU (2) HUE031304T2 (h)
IL (1) IL178152A (h)
LT (1) LT2570128T (h)
LU (1) LU92565I2 (h)
MA (1) MA28631B1 (h)
MX (1) MXPA06012405A (h)
MY (1) MY144753A (h)
NL (1) NL300694I2 (h)
NO (3) NO338959B1 (h)
NZ (1) NZ549997A (h)
PE (1) PE20060259A1 (h)
PL (2) PL1740177T3 (h)
PT (2) PT1740177E (h)
SG (1) SG186597A1 (h)
SI (2) SI2570128T1 (h)
TW (1) TWI363759B (h)
UA (1) UA95768C2 (h)
UY (1) UY28871A1 (h)
WO (1) WO2005104745A2 (h)
ZA (1) ZA200608565B (h)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519108A (en) * 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1677796A4 (en) * 2003-10-17 2006-12-27 Glaxo Group Ltd MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
JP2007528420A (ja) * 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005095407A1 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) * 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
ATE405263T1 (de) * 2004-04-05 2008-09-15 Samaritan Pharmaceuticals Inc Anti-hiv-chinuklidinverbindungen
MY144753A (en) 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) * 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
WO2006055553A2 (en) * 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
EP1937267A4 (en) * 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
US7767691B2 (en) * 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CA2659539A1 (en) 2006-08-01 2008-02-07 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
AR070564A1 (es) 2008-02-06 2010-04-21 Glaxo Group Ltd Derivados de 1h-pirazolo[3,4-b]piridin-5-ilo,inhibidores de fosfodiesterasas pde4 y antagonistas de receptores muscarinicos de acetilcolina(machr), utiles en el tratamiento y/o profilaxis de enfermedades respiratorias y alergicas,y composiciones farmaceuticas que los comprenden
CL2009000249A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo[3,4-b] piridin-butanodiamida; composicion farmaceutica; y su uso en el tratamiento del asma, enfermedad pulmonar obstructiva cronica, rinitis, dermatitis atopica, psoriasis.
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
ES2994042T3 (en) 2009-02-26 2025-01-16 Glaxo Group Ltd Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
WO2010102958A1 (en) 2009-03-09 2010-09-16 Glaxo Group Limited 4-oxadiazol-2 -yl- indazoles as inhibitors of p13 kinases
EP2406249A1 (en) 2009-03-10 2012-01-18 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
TWI562992B (en) 2009-04-30 2016-12-21 Glaxo Group Ltd Indazole derivative, pharmaceutical composition thereof, and use thereof as inhibitors of kinase activity
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
WO2011067366A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
WO2011067364A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Novel compounds
ES2655083T3 (es) * 2010-01-28 2018-02-16 Theron Pharmaceuticals, Inc. Derivados de 7-azoniabiciclo [2.2.1]heptano, métodos de producción, y usos farmacéuticos de estos
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
AU2011269238A1 (en) * 2010-06-22 2013-01-10 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
ES2548036T3 (es) 2010-09-08 2015-10-13 Glaxosmithkline Intellectual Property Development Limited Polimorfos y sales de N-[5-[4-(5-{[(2R,6S)-2,6-dimetil-4-morfolinil]metil}-1,3-oxazol-2-il)-1H-indazol-6-il]-2-(metiloxi)-3-piridinil]metanosulfonamida
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20140113888A1 (en) * 2011-06-08 2014-04-24 Glaxo Group Limited Novel Combination of Therapeutic Agents
US20140116434A1 (en) 2011-06-08 2014-05-01 Glaxo Group Limited Dry Powder Inhaler Compositions
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 集合粒子
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
EP2885298B1 (en) 2012-08-15 2018-06-13 Glaxo Group Limited Chemical process
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
EP3023424B1 (en) * 2013-07-13 2019-02-27 Beijing Shuobai Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
AU2014297993A1 (en) * 2013-07-30 2016-02-04 Glaxosmithkline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
EP3057588A1 (en) 2013-10-17 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
AU2014336250A1 (en) 2013-10-17 2016-04-14 Glaxosmithkline Intellectual Property Development Limited PI3K inhibitor for treatment of respiratory disease
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
WO2015181262A1 (en) 2014-05-28 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
WO2016071792A1 (en) 2014-11-03 2016-05-12 Laboratorio Chimico Internazionale S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
ES2973972T3 (es) * 2016-01-08 2024-06-25 Theron Pharmaceuticals Inc Composiciones de derivados de 7-azoniabiciclo[2.2.1]heptano para inhaladores de polvo seco
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
US20190161480A1 (en) 2016-08-08 2019-05-30 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
PT109740B (pt) * 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
BR112022019245A2 (pt) 2020-03-26 2022-11-16 Glaxosmithkline Ip Dev Ltd Inibidores de catepsina para prevenir ou tratar infecções virais
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
AU2021264829B2 (en) * 2020-04-26 2024-02-01 Beijing Showby Pharmaceutical Co., Ltd. Crystal of M receptor antagonist as well as preparation method therefor and application thereof
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440B (pt) 2021-09-03 2024-04-26 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting
WO2024251812A1 (en) 2023-06-07 2024-12-12 Pharmazell Gmbh A process for the preparation of umeclidinium bromide intermediate

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (h) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
ATE23272T1 (de) 1981-07-08 1986-11-15 Draco Ab Pulverinhalator.
IN160851B (h) 1982-10-08 1987-08-08 Glaxo Group Ltd
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
EP0211595B1 (en) 1985-07-30 1991-11-13 Glaxo Group Limited Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
WO1998024788A1 (en) 1996-12-02 1998-06-11 Georgetown University Tropane derivatives and method for their synthesis
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
CN1250545C (zh) * 2000-12-28 2006-04-12 阿尔米雷尔普罗迪斯制药有限公司 新的奎宁环衍生物类及含有这类衍生物的药物组合物
BR0212983A (pt) 2001-10-17 2004-10-13 Ucb Sa Composto, uso do composto, e, intermediários de sìntese
CA2466344A1 (en) * 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
BR0215348A (pt) * 2001-12-20 2004-11-16 S A L V A T Lab Sa Derivados de carbamato de 1-alquil-1-azoniabiciclo[2-2]octano e uso destes como antagonistas do receptor muscarìnico
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
WO2004091482A2 (en) 2003-04-07 2004-10-28 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
TW200519108A (en) 2003-07-17 2005-06-16 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
AR045913A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
PE20050711A1 (es) 2003-07-17 2005-09-10 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1] octanos como antagonistas de los receptores muscarinicos de la acetilcolina
CN101230062A (zh) 2003-10-14 2008-07-30 葛兰素集团有限公司 蕈毒碱性乙酰胆碱受体拮抗剂
EP1677796A4 (en) 2003-10-17 2006-12-27 Glaxo Group Ltd MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
US7345060B2 (en) 2003-11-21 2008-03-18 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
UY28645A1 (es) 2003-12-03 2005-06-30 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200530226A (en) 2003-12-03 2005-09-16 Glaxo Group Ltd Novel M3 muscarinic acetylcholine receptor antagonists
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
US20070179131A1 (en) 2004-03-11 2007-08-02 Jian Jin Novel M3 Muscarinic Acetylcholine Receptor Antagonists
JP2007528420A (ja) 2004-03-11 2007-10-11 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2005095407A1 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2005094251A2 (en) 2004-03-17 2005-10-13 Glaxo Group Limited M3muscarinic acetylcholine receptor antagonists
JP2007529512A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
EP1725241A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC M3 RECEPTOR
JP2007538005A (ja) 2004-04-07 2007-12-27 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
MY144753A (en) * 2004-04-27 2011-10-31 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
WO2005112644A2 (en) 2004-05-13 2005-12-01 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
PE20060367A1 (es) 2004-05-28 2006-04-28 Glaxo Group Ltd Compuestos 8-azoniabiciclo[3.2.1]octanos como antagonistas del receptor de acetilcolina muscarinico
EP1765339A4 (en) 2004-06-30 2009-09-02 Glaxo Group Ltd ANTAGONISTS OF MUSCARIN ACETYLCHOLIN RECEPTOR
JP2008509159A (ja) 2004-08-05 2008-03-27 グラクソ グループ リミテッド ムスカリン性アセチルコリン受容体拮抗薬
US20090076061A1 (en) 2004-08-06 2009-03-19 Jakob Busch-Petersen Muscarinic acetycholine receptor antagonists
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
WO2006055503A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2006055553A2 (en) 2004-11-15 2006-05-26 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
EP1937267A4 (en) 2005-08-02 2009-08-26 Glaxo Group Ltd M3-MUSCARIN ACETYLCHOLIN RECEPTOR ANTAGONISTS
JP2009503101A (ja) 2005-08-02 2009-01-29 グラクソ グループ リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US7767691B2 (en) 2005-08-18 2010-08-03 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists containing an azoniabiocyclo[2.2.1] heptane ring system
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
US20070185155A1 (en) 2007-08-09
US8853404B2 (en) 2014-10-07
EP1740177B1 (en) 2012-08-08
BRPI0510170B8 (pt) 2021-05-25
US7488827B2 (en) 2009-02-10
MA28631B1 (fr) 2007-06-01
HRP20161385T1 (hr) 2016-12-02
ECSP066940A (es) 2006-12-20
CA2755954A1 (en) 2005-11-10
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
FR14C0075I2 (fr) 2015-05-22
BRPI0510170B1 (pt) 2018-12-18
SI2570128T1 (sl) 2016-11-30
DK1740177T3 (da) 2012-10-29
KR20110010841A (ko) 2011-02-07
IL178152A (en) 2011-05-31
EP1740177A2 (en) 2007-01-10
US9144571B2 (en) 2015-09-29
EA201100019A1 (ru) 2011-12-30
US20150238470A1 (en) 2015-08-27
NO338959B1 (no) 2016-11-07
NL300694I1 (h) 2015-12-29
PE20060259A1 (es) 2006-03-25
LU92565I9 (h) 2019-01-17
JP2012162559A (ja) 2012-08-30
AP2006003746A0 (en) 2006-10-31
KR101037026B1 (ko) 2011-05-25
US8183257B2 (en) 2012-05-22
CA2564742A1 (en) 2005-11-10
EP1740177A4 (en) 2010-05-05
CA2564742C (en) 2012-01-10
WO2005104745A3 (en) 2006-08-03
CY2014043I2 (el) 2015-12-09
KR101152032B1 (ko) 2012-06-11
EA021994B1 (ru) 2015-10-30
FR14C0075I1 (fr) 2014-11-21
JP5398871B2 (ja) 2014-01-29
CY2014043I1 (el) 2015-12-09
US8309572B2 (en) 2012-11-13
NO2017018I1 (no) 2017-05-04
US20160002220A1 (en) 2016-01-07
US7498440B2 (en) 2009-03-03
ES2392848T4 (es) 2014-10-01
SI1740177T1 (sl) 2012-12-31
CA2755954C (en) 2014-02-18
ES2392848T3 (es) 2012-12-14
EA200601991A1 (ru) 2007-02-27
NZ549997A (en) 2010-10-29
US20140371264A1 (en) 2014-12-18
TW200605887A (en) 2006-02-16
UY28871A1 (es) 2005-11-30
US20090124653A1 (en) 2009-05-14
LT2570128T (lt) 2016-10-10
WO2005104745A2 (en) 2005-11-10
US8575347B2 (en) 2013-11-05
EP2570128B1 (en) 2016-08-10
DK2570128T3 (en) 2016-11-07
NL300694I2 (h) 2015-12-29
EA015033B1 (ru) 2011-04-29
PL1740177T3 (pl) 2012-12-31
LU92565I2 (fr) 2014-12-02
US20130030015A1 (en) 2013-01-31
AP2213A (en) 2011-03-01
HUE031304T2 (hu) 2017-07-28
NO2017017I1 (no) 2017-05-04
CN1976701A (zh) 2007-06-06
AU2005237576B2 (en) 2012-01-12
SG186597A1 (en) 2013-01-30
EP2570128A1 (en) 2013-03-20
ZA200608565B (en) 2019-12-18
MXPA06012405A (es) 2007-01-17
CN102040602A (zh) 2011-05-04
AU2005237576A1 (en) 2005-11-10
AR050902A1 (es) 2006-12-06
JP2007534769A (ja) 2007-11-29
PL2570128T3 (pl) 2017-09-29
KR20070015412A (ko) 2007-02-02
ES2600405T3 (es) 2017-02-08
CY1113196T1 (el) 2015-12-09
JP5014121B2 (ja) 2012-08-29
NO2017018I2 (no) 2018-05-14
PT2570128T (pt) 2016-10-07
HUS1400053I1 (hu) 2017-07-28
HK1102423A1 (en) 2007-11-23
BRPI0510170A (pt) 2007-10-02
EP3111936A1 (en) 2017-01-04
UA95768C2 (ru) 2011-09-12
NO20065417L (no) 2006-12-29
PT1740177E (pt) 2012-11-02
MY144753A (en) 2011-10-31
US20120157491A1 (en) 2012-06-21
HRP20120832T1 (hr) 2012-11-30
CY1118082T1 (el) 2017-06-28
US9045469B2 (en) 2015-06-02
TWI363759B (en) 2012-05-11
IL178152A0 (en) 2006-12-31

Similar Documents

Publication Publication Date Title
BE2024C508I2 (h)
BE2022C549I2 (h)
BE2023C542I2 (h)
BE2021C001I2 (h)
BE2020C513I2 (h)
BE2020C517I2 (h)
BE2019C540I2 (h)
BE2019C523I2 (h)
BE2019C506I2 (h)
BE2019C548I2 (h)
BE2018C045I2 (h)
BE2020C525I2 (h)
BE2017C063I2 (h)
BE2017C027I2 (h)
BE2017C023I2 (h)
BE2015C041I2 (h)
BE2015C038I2 (h)
BE2015C014I2 (h)
BE2015C015I2 (h)
BE2014C071I2 (h)
IN2014DN10707A (h)
BE2014C064I2 (h)
BE2014C063I2 (h)
BE2014C010I2 (h)
BE2014C014I2 (h)